Percutaneous Electrolysis for the Management of Musculoskeletal Disorders. A Systematic Review With Meta‐Analysis
Physiotherapy Research International · 2026
DOI: 10.1002/pri.70352 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Physiotherapy Research International, 2026. Verfasst von Tereza Novaková und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiotherapy, Faculty of Physical Education and Sport, Karlova University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Electrolysis, Exercise Therapy, Musculoskeletal Diseases, Myofascial Pain Syndromes. Die Arbeit nennt 57 Literaturangaben.
Abstract (Originalsprache)
Background and Purpose To evaluate the effectiveness of percutaneous electrolysis (PNE), alone or combined with therapeutic exercise (TE), on pain intensity and function in patients with tendinopathy or myofascial pain syndrome. Methods A systematic review with meta‐analysis was conducted following PRISMA guidelines and registered in PROSPERO (CRD420251238941). Searches were performed in PubMed, Web of Science, and PEDro from inception to November 2025, in accordance with the PRISMA guidelines. Randomized controlled trials comparing PNE with sham, control, or dry needling (DN) interventions were included. Pain intensity and function were analyzed using random‐effect meta‐analyses, and the certainty of evidence was assessed using GRADE. Results/Findings Thirteen trials were included in the qualitative synthesis and twelve in the meta‐analysis. In tendinopathies, very low‐certainty evidence indicated that adding PNE to TE was not superior to sham plus TE or TE alone for pain or function at short‐, medium‐, or long‐term follow‐up. Low‐certainty evidence showed that PNE combined with TE resulted in greater short‐ and medium‐term pain reduction compared with DN plus TE without functional superiority. In myofascial pain syndrome, low to very low‐certainty evidence demonstrated no significant differences between PNE and DN for pain or function at any follow‐up. Implications for Physiotherapy Practice Current evidence does not support the superiority of PNE over sham or control interventions when added to therapeutic exercise. PNE may provide short‐ to medium‐term pain benefits compared with DN in tendinopathy but not in myofascial pain syndrome. Further high‐quality trials are required to clarify its clinical role. Trail Registration The protocol of this study was registered in PROSPERO (PROSPERO registration: CRD420251238941).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiotherapy, Faculty of Physical Education and Sport, Karlova University, Prague, Czech Republic.
- Department of Surgery, Ophthalmology, Otorhinolaryngology and Physiotherapy, Faculty of Health Sciences, University of Valladolid, Soria and Valladolid, Spain.
- Department of Physiotherapy, Faculty of Medicine and Health Sciences, International University of Catalonia, Barcelona, Spain.
ORCID-Profile: Tereza Novaková, Milan Martinek, Andoni Carrasco-Uribarren, Helena Vomáčková, Luis Ceballos-Laita
Zitieren
APA
Novaková, T., Robles-Pérez, R., Martinek, M., Carrasco-Uribarren, A., Vomáčková, H., & Ceballos-Laita, L. (2026). Percutaneous Electrolysis for the Management of Musculoskeletal Disorders. A Systematic Review With Meta‐Analysis. Physiotherapy Research International. https://doi.org/10.1002/pri.70352
Vancouver
Novaková T, Robles-Pérez R, Martinek M, Carrasco-Uribarren A, Vomáčková H, Ceballos-Laita L. Percutaneous Electrolysis for the Management of Musculoskeletal Disorders. A Systematic Review With Meta‐Analysis. Physiotherapy Research International. 2026. doi:10.1002/pri.70352
BibTeX
@article{Novakov2026,
author = {Novaková, Tereza and Robles-Pérez, Román and Martinek, Milan and Carrasco-Uribarren, Andoni and Vomáčková, Helena and Ceballos-Laita, Luis},
title = {Percutaneous Electrolysis for the Management of Musculoskeletal Disorders. A Systematic Review With Meta‐Analysis},
journal = {Physiotherapy Research International},
year = {2026},
doi = {10.1002/pri.70352}
}
EUVIMED